CCR 20th anniversary commentary: In the beginning, there was PS-341.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25733705.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2549 and PMC identifier 4349205.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Proteasome inhibitors have a 20-year history in cancer therapy. The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003. Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708).
Medical subject headings
- Antineoplastic Agents
- Bortezomib
- Proteasome Inhibitors